Defects in immune system enzyme may increase risk of autoimmune disorders

June 16, 2010

A multi-institutional research team has found that rare variants in the gene coding an enzyme that controls the activity of a key immune cell occur more frequently in individuals with autoimmune disorders like rheumatoid arthritis and type 1 diabetes. Their report, which will appear in the journal Nature and is receiving early online release, identifies a pathway that could be a therapeutic target and may present a model for future investigations of the role of rare gene variants in common disorders.

"Pathways that involve rare disease-associated variants may point the way to therapies," explains Shiv Pillai, MD, PhD, of the Massachusetts General Hospital (MGH) Cancer Center, senior author of the Nature paper. "Our approach of identifying rare variants by detailed examination of the gene sequence, followed by in vitro functional studies and analysis of effects in patients, could be a template for future full-genome studies."

Earlier research conducted by Pillai's team, in collaboration with investigators at the University of California at San Diego, found that mice in which the gene for an enzyme called sialic acid acetylesterase (SIAE) was knocked out developed a condition similar to the autoimmune disease lupus. SIAE normally controls the activity of B cells, which produce antibodies after encountering and recognizing foreign antigens. Without the inhibiting action of SIAE, B cells that react against an individual's own "self" tissues could be released into circulation, possibly resulting in an autoimmune disease. The current study was designed to investigate whether SIAE defects have a role in human autoimmune disease.

Most studies searching for genetic contributions to common diseases have been genome-wide association studies (GWAS), which scan key markers across participants' genomes to find variations that are more frequent in those affected by a particular disorder. These scans have identified some common variants associated with conditions such as heart disease, cholesterol levels, type 2 diabetes, and some autoimmune disorders; but in general the contribution of these variants to disease susceptibility has been very small. GWAS approaches have not linked any variants in SIAE to human autoimmunity; however, since such studies do not scan each base pair in every gene, they cannot find variants that occur rarely in the general population but more frequently in affected individuals.

To more fully investigate the possible contribution of rare SIAE variants to human autoimmunity, the researchers completely scanned the protein-coding portions of the SIAE gene in blood samples from a total of 923 individuals with common autoimmune disorders and 648 control participants. Variants that interfered with either the activity or the secretion of the enzyme were found in 24 autoimmune participants and 2 of the controls, indicating that these changes were almost nine times more common in patients with autoimmune disease than in controls. One variant only prevented the secretion of SIAE if inherited from both parents, but the other 11 identified variants interfered with the enzyme's activity when only a single gene copy was altered.

"While loss-of-function variants in SIAE itself account for only about 2 or 3 percent of autoimmune cases, Pillai explains, "we are actively investigating other genes in this pathway that may be defective in a larger percentage of patients. We're also identifying subsets of patients with SIAE defects who may be candidates for several approaches to alleviate or even correct the defects." Pillai is an associate professor of Medicine at Harvard Medical School.
-end-
Co-lead authors of the Nature paper - all from the MGH Center for CancerResearch - are Ira Surolia, MD, MPH, Stephan Pirnie, Vasant Chellappa, PhD, Kendra Taylor, PhD, and Annaiah Cariappa, MD. Additional collaborators from several institutions provided patient DNA samples for the study, which was supported by grants from the National Institutes of Health, the Alliance for Lupus Research and the MGH Center for the Study of Inflammatory Bowel Disease.

Massachusetts General Hospital, established in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $600 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, systems biology, transplantation biology and photomedicine.

Massachusetts General Hospital

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.